Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ruxolitinib withdrawal syndrome leading to tumor lysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Oct 2013

Dai Tong, Friedman Ellen W, Barta Stefan K

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Mutation
Share to Aged
Share to Nitriles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 23752116
DOI: 10.1200/JCO.2012.47.6473

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ruxolitinib withdrawal syndrome leading to tumor lysis.PMID 23752116Read ↗

Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass.Semantic proximity Read ↗

Trousseau's syndrome triggered by an immune checkpoint blockade in a non‐small cell lung cancer patientSemantic proximity Read ↗

Tumor Lysis Syndrome in a Patient with BRAFV600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib.Semantic proximity Read ↗

A vanishing act: the incredible erlotinib.Semantic proximity Read ↗

Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problemSemantic proximity Read ↗

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.Semantic proximity Read ↗

Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.Semantic proximity Read ↗

Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events.Semantic proximity Read ↗

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.Semantic proximity Read ↗

Management of Refractory Immune Thrombocytopenia with Fostamatinib: A Case ReportSemantic proximity Read ↗

Erlotinib.Semantic proximity Read ↗

Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.